Valneva (VALN) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Valneva has announced promising three-year data for its single-dose chikungunya vaccine, IXCHIQ®, which maintains strong antibody levels in both younger and older adults. The vaccine is approved in the US, Europe, and Canada, and Valneva is working to expand its use to adolescents and in regions with limited vaccine access. Supported by significant funding, the company is also pursuing marketing authorization in Brazil and aims to broaden access in low and middle-income countries.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
